 | |
| Clinical data | |
|---|---|
| Trade names | Hycamtin, Potactasol |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610007 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous infusion, by mouth (capsules) |
| Drug class | Topoisomerase inhibitor[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 31.4 % in humans[2][3] |
| Protein binding | 35% |
| Metabolism | Liver |
| Elimination half-life | 2–3 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C23H23N3O5 |
| Molar mass | 421.453 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Topotecan, sold under the brand name Hycamtin among others, is a medication used to treat ovarian cancer, cervical cancer, and lung cancer.[4] It is used when other treatments have failed.[4] It is given by mouth or by injection into a vein.[4][1]
Common side effects include low white blood cells, low platelets, fever, low red blood cells, nausea, diarrhea, mouth sores, and hair loss.[4] Use during pregnancy may harm the baby.[1] It is a topoisomerase inhibitor and works by interfering with the ability of cells to make DNA.[1]
Topotecan was approved for medical use in Europe and the United States in 1996.[4][1] It is available as a generic medication.[5] It costs about 127 USD for 4 mg for injection in the United States as of 2021.[6] In the United Kingdom 10 tablets of 0.25 mg costs about £75.[5]
References edit
- ^ a b c d e "Topotecan Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 8 October 2021.
- ^ Léger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, et al. (December 2004). "Mechanism-based models for topotecan-induced neutropenia". Clinical Pharmacology and Therapeutics. 76 (6): 567–78. doi:10.1016/j.clpt.2004.08.008. PMID 15592328. S2CID 37527965.
- ^ Gelderblom H, Loos WJ, Sissung TM, Burger H, Nooter K, Soepenberg O, et al. (July 2004). "Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan". Journal of Clinical Oncology. 22 (14 suppl): 2015. doi:10.1200/jco.2004.22.90140.2015. PMID 28015603.
- ^ a b c d e f g "Hycamtin". Archived from the original on 26 February 2021. Retrieved 8 October 2021.
- ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 979. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Topotecan Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 February 2021. Retrieved 8 October 2021.